Skip to main content
Equibles

Christopher Senner

CFO

Exelixis, Inc. (EXEL)

Equibles does not estimate personal net worth.

Get an email with a short summary when Exelixis, Inc. publishes a filing, an earnings call transcript or a press release.

Get EXEL alerts

About Christopher Senner

Christopher Senner is recorded as CFO at Exelixis, Inc. (EXEL). The newest filing on record that lists Christopher Senner as CFO at Exelixis, Inc. (EXEL) is dated April 15, 2026. The proxy statement of Exelixis, Inc. reports total compensation of $10,648,472 for Christopher Senner in fiscal 2025, including a base salary of $822,823. Disclosed compensation is on record for 9 fiscal years. Christopher Senner has spoken on 12 earnings calls across 1 company, most recently for Exelixis, Inc. on October 29, 2026. Exelixis, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Exelixis, Inc. includes Michael M. Morrissey (CEO and Board Member), Michael Morrissey (CEO and Board Member), Brenda Hefti, J.D., Ph.D. (General Counsel) and 7 others.

Christopher Senner on recent calls

“For the third quarter, 2026, the company reported total revenues of approximately $659 million, which included Cabo's Antitip franchise U.S. net product revenues of $605 million.”
CFO, Exelixis Q3 2026 Financial Results Conference Call ·
“For the fourth quarter 2025, the company reported total revenues of approximately $599 million, which included cabozantinib franchise net product revenues of $546.6 million.”
CFO, Exelixis, Inc. Q4 FY2025 Earnings Call ·
“For the third quarter of 2025, the company reported total revenues of approximately $598 million, which included cabozantinib franchise NET product revenues of approximately $543 million.”
CFO, Exelixis, Inc. Q3 FY2025 Earnings Call ·
“For the second quarter of 2025, the company reported total revenues of approximately $568 million, which included cabozantinib franchise net product revenues of $520 million.”
CFO, Exelixis, Inc. Q2 FY2025 Earnings Call ·
“For the first quarter 2025, the company reported total revenues of approximately $555 million, which included cabozantinib franchise net product revenues of $513.3 million.”
CFO, Exelixis, Inc. Q1 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Exelixis, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Exelixis, Inc. (EXEL) $822,823 $10,648,472
2024 Exelixis, Inc. (EXEL) $788,288 $4,680,160
2023 Exelixis, Inc. (EXEL) $746,726 $4,947,631
2022 Exelixis, Inc. (EXEL) $716,172 $5,182,270
2021 Exelixis, Inc. (EXEL) $679,568 $2,457,112
2020 Exelixis, Inc. (EXEL) $648,358 $1,064,968
2019 Exelixis, Inc. (EXEL) $622,866 $942,259
2018 Exelixis, Inc. (EXEL) $594,740 $2,168,814
2017 Exelixis, Inc. (EXEL) $562,120 $3,890,358

Recent activity